At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...
The combination of Keytruda (pembrolizumab) and Welireg (belzutifan) improved disease-free survival compared with Keytruda ...
The third and final day of the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium highlighted important developments in kidney cancer treatment, including combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results